Pfizer Q2 net profit rises 19% YoY; strong growth in sales and margins

Pfizer Ltd reported a healthy performance for the September quarter (Q2 FY26), posting a 19.4% year-on-year rise in net profit to ₹189 crore, compared to ₹158 crore in the same period last year. The growth was supported by strong sales momentum and improved operational efficiency.

The company's revenue from operations rose 9.1% YoY to ₹642.3 crore, reflecting steady demand across key therapeutic segments.

#2QWithCNBCTV18 | #Pfizer reports #Q2Results:

▶️Net profit up 19.4% at ₹189 Cr Vs ₹158 Cr (YoY)

▶️Revenue up 9.1% at ₹642.3 Cr Vs ₹588.6 Cr (YoY)

▶️EBITDA up 21.5% at ₹229.8 Cr Vs ₹189.2 Cr (YoY)

▶️Margin at 35.8% Vs 32.1% (YoY) pic.twitter.com/LBoNd4WRRQ

— CNBC-TV18 (@CNBCTV18Live) November 12, 2025

EBITDA for the quarter stood at ₹229.8 crore, up 21.5% from ₹189.2 crore last year, while EBITDA margins improved significantly to 35.8% from 32.1%, aided by cost optimisation.

The company highlighted that during the quarter ended

March 31, 2025, it had received approvals from the Maharashtra Industrial Development Corporation (MIDC) for the assignment and sale of its leased land and building assets, completing the transfer with a net gain of ₹172.81 crore, disclosed as an exceptional item in its financials.

In the exchange filing, the company said that at its annual general meeting on July 21, 2025, shareholders approved a total dividend payout of ₹165 per equity share (1,650% of face value ₹10).

This comprised a final dividend of ₹35, a special dividend of ₹100 marking Pfizer’s 75th year in India, and an additional ₹30 per share special dividend linked to the MIDC asset sale gain.

The dividend was distributed on July 25, 2025.

Shares of the company ended higher on Wednesday (November 12) by 0.48% at ₹5,021.00 on the NSE.

Also Read: Asian Paints Q2 Results: Stock surges over 6% after strong domestic volume growth